(Circulation. 1999;99:1147-1155.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Endothelin-1 and Its mRNA in the Wall Layers of Human Arteries Ex Vivo
From the Departments of Clinical and Experimental Medicine (G.P.R., S.C., E.P., G.A., F.D.R., P.P., A.C.P.), Cardiac Surgery (G.G., D.C.), and Biomedical Sciences and CNR Unit for Muscle Biology and Physiopathology (S.S.), University of Padova, Italy.
Correspondence to Gian Paolo Rossi, MD, FACC, Department of Clinical and Experimental Medicine, Clinica Medica 4, University Hospital, via Giustiniani, 2, 35126 Padova, Italy. E-mail gprossi{at}ux1.unipd.it
Background—The participation of endothelin-1 (ET-1) in the control of vascular tone in humans has been questioned, on the basis of the finding of subthreshold immunoreactive (ir) ET-1 plasma levels. However, because most ET-1 is secreted abluminally, it might attain a higher concentration in the tunica media than in plasma. Furthermore, evidence indicates that vascular smooth muscle cells (VSMCs) can synthesize ET-1 on stimulation in vitro. We therefore looked for irET-1 in the different layers of the wall of human arteries, including renal, gastric, and internal thoracic artery wall, obtained ex vivo from consenting patients with coronary artery disease and/or high blood pressure undergoing surgery, as well as from young organ donors.
Methods and Results—We performed immunohistochemistry with specific anti–ET-1 and anti-vWF antibodies followed by detection with an avidin-biotin complex ultrasensitive kit. The presence of preproET-1 and human endothelin-converting enzyme-1 (hECE-1) mRNA was also investigated by reverse transcription–polymerase chain reaction in homogenates of vessel wall, including preparations deprived of both endothelium and adventitia, and in isolated VSMCs. We detected irET-1 in the endothelium of all arteries and in the tunica media of internal thoracic artery from most patients with coronary artery disease. PreproET-1 and hECE-1 mRNA was also detected in VSMCs isolated from these vessels. irET-1 and irvWF staining in endothelium and tunica media was measured by use of microscope-coupled computer-assisted technology. Significant correlations between the amount of irET-1 in the tunica media and mean blood pressure (P<0.05), total serum cholesterol (P<0.05), and number of atherosclerotic sites (P<0.001) were found. Thus, in organ donors, irET-1 was detectable almost exclusively in endothelial cells, whereas in patients with coronary artery disease and/or arterial hypertension, sizable amounts of irET-1 were detectable in the tunica media of different types of arteries. In addition, VSMCs isolated from these vessels coexpressed the preproET-1 and hECE-1 genes.
Conclusions—Collectively, these findings are consistent with the contention that endothelial damage occurs in most patients with atherosclerosis and/or hypertension and that ET-1 is synthesized in VSMCs of these patients.
Key Words: arteries • endothelin • antibodies • RNA
This article has been cited by other articles:
 |
|
 |
|
  P. Martinez-Miguel, V. Raoch, C. Zaragoza, J. M. Valdivielso, M. Rodriguez-Puyol, D. Rodriguez-Puyol, and S. Lopez-Ongil Endothelin-converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low density lipoproteins J. Lipid Res., March 1, 2009; 50(3): 364 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb Role of Endothelin-1 in Clinical Hypertension: 20 Years On Hypertension, September 1, 2008; 52(3): 452 - 459. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chansel, M. Ciroldi, S. Vandermeersch, L. F Jackson, A.-M. Gomez, D. Henrion, D. C. Lee, T. M. Coffman, S. Richard, J.-C. Dussaule, et al. Heparin binding EGF is necessary for vasospastic response to endothelin FASEB J, September 1, 2006; 20(11): 1936 - 1938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Muller, R. A. Catar, B. Niemann, M. Barton, L. Knels, M. Wendel, and H. Morawietz Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins. Experimental Biology and Medicine, June 1, 2006; 231(6): 766 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dhaun, J. Goddard, and DavidJ. Webb The Endothelin System and Its Antagonism in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Sutherland, M. I. Nataatmadja, P. J. Walker, L. Cuttle, R. B. Garlick, and M. J. West Vascular Remodeling in the Internal Mammary Artery Graft and Association With In Situ Endothelin-1 and Receptor Expression Circulation, March 7, 2006; 113(9): 1180 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Thomson, P. Kumarathasan, P. Goegan, R. A. Aubin, and R. Vincent Differential Regulation of the Lung Endothelin System by Urban Particulate Matter and Ozone Toxicol. Sci., November 1, 2005; 88(1): 103 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kruger, J. Graf, D. Kunz, T. Stickel, M. W. Merx, P. Hanrath, and U. Janssens Urotensin II in patients with chronic heart failure Eur J Heart Fail, June 1, 2005; 7(4): 475 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Woods, E. G. Wood, S. C. Bardswell, D. Bishop-Bailey, S. Barker, S. J. Wort, J. A. Mitchell, and T. D. Warner Role for Nuclear Factor-{kappa}B and Signal Transducer and Activator of Transcription 1/Interferon Regulatory Factor-1 in Cytokine-Induced Endothelin-1 Release in Human Vascular Smooth Muscle Cells Mol. Pharmacol., October 1, 2003; 64(4): 923 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Spieker, D. Hurlimann, F. Ruschitzka, R. Corti, F. Enseleit, S. Shaw, D. Hayoz, J. E. Deanfield, T. F. Luscher, and G. Noll Mental Stress Induces Prolonged Endothelial Dysfunction via Endothelin-A Receptors Circulation, June 18, 2002; 105(24): 2817 - 2820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Martin, D. Ninio, and H. Krum Effect of Endothelin Blockade on Basal and Stimulated Forearm Blood Flow in Patients With Essential Hypertension Hypertension, March 1, 2002; 39(3): 821 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iglarz, J. Benessiano, I. Philip, S. Vuillaumier-Barrot, S. Lasocki, U. Hvass, G. Durand, J.-M. Desmonts, B. I. Levy, and D. Henrion Preproendothelin-1 Gene Polymorphism Is Related to a Change in Vascular Reactivity in the Human Mammary Artery In Vitro Hypertension, February 1, 2002; 39(2): 209 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-D. Orzechowski, A. Gunther, S. Menzel, A. Zimmermann, H. Funke-Kaiser, R. Real, T. Subkowski, F. S. Zollmann, and M. Paul Transcriptional Mechanism of Protein Kinase C-Induced Isoform-Specific Expression of the Gene for Endothelin-Converting Enzyme-1in Human Endothelial Cells Mol. Pharmacol., December 1, 2001; 60(6): 1332 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Spieker, G. Noll, F. T. Ruschitzka, and T. F. Luscher Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1493 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Jhund, N. Dawson, A. P. Davie, N. Sattar, J. Norrie, K. P. J. O'Kane, and J. J. V. McMurray Attenuation of endothelin-1 induced vasoconstriction by 17{beta} estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1367 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Hand, W. G. Haynes, and D. J. Webb Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure Nephrol. Dial. Transplant., February 1, 2001; 16(2): 295 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ungvari and A. Koller Endothelin and Prostaglandin H2/Thromboxane A2 Enhance Myogenic Constriction in Hypertension by Increasing Ca2+ Sensitivity of Arteriolar Smooth Muscle Hypertension, November 1, 2000; 36(5): 856 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Grantham, J. A. Schirger, P. W. Wennberg, S. Sandberg, D. M. Heublein, T. Subkowski, and J. C. Burnett Jr Modulation of Functionally Active Endothelin-Converting Enzyme by Chronic Neutral Endopeptidase Inhibition in Experimental Atherosclerosis Circulation, April 25, 2000; 101(16): 1976 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Gilbert, J. R. Rumble, Z. Cao, A. J. Cox, P. van Eeden, T. J. Allen, D. J. Kelly, and M. E. Cooper Endothelin Receptor Antagonism Ameliorates Mast Cell Infiltration, Vascular Hypertrophy, and Epidermal Growth Factor Expression in Experimental Diabetes Circ. Res., February 4, 2000; 86(2): 158 - 165. [Abstract] [Full Text] [PDF]
|
|